‘Sleeper Issue:’ How Part B Drugs May Be Impacted By Medicare Part D Redesign
If changes to stand-alone Part D plans mandated by the IRA drive a switch to MA plans, the changing enrollment could drive more uptake of physician-administered drugs – but also more utilization management.
You may also be interested in...
More impactful benefit changes coming in 2025; will destabilization among standalone plans follow?
Increased application of utilization management controls expected as plans face higher costs under the redesign. However, the formulary advantages available to drugs in the protected classes may lead developers to sharpen their focus on those categories.
Pulling the controversial Alzheimer’s drug’s BLA should not exempt Biogen from fulfilling ClinicalTrials.gov reporting requirements for two key studies, even if the research gets terminated, former head of the NIH data repository tells the Pink Sheet.